BACKGROUND The ongoing coronavirus disease (COVID)-19 pandemic caused by severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) might be controlled by an …

Since its emergence in late 2019, the coronavirus disease 2019 (COVID‐19) pandemic has
caused substantial morbidity and mortality. Despite the availability of efficacious vaccines, …

Background The Ad26.COV2.S vaccine is a recombinant, replication-incompetent human
adenovirus type 26 vector encoding full-length severe acute respiratory syndrome coronavirus …

Background Efficacious vaccines are urgently needed to contain the ongoing coronavirus
disease 2019 (Covid-19) pandemic of infection with severe acute respiratory syndrome …

The Ad26.COV2.S vaccine 1 , 2 – 3 has demonstrated clinical efficacy against symptomatic
COVID-19, including against the B.1.351 variant that is partially resistant to neutralizing …

Background The Ad26.COV2.S vaccine was highly effective against severe–critical coronavirus
disease 2019 (Covid-19), hospitalization, and death in the primary phase 3 efficacy …

Importance Control of the global COVID-19 pandemic will require the development and
deployment of safe and effective vaccines. Objective To evaluate the immunogenicity of the Ad26…

Durability of Response after Ad26.COV2.S Vaccination In this study, investigators measured
immune responses in 20 participants who had received either one or two doses of the Ad26.…

Measuring immune correlates of disease acquisition and protection in the context of a clinical
trial is a prerequisite for improved vaccine design. We analysed binding and neutralizing …

Importance Antibody responses elicited by current messenger RNA (mRNA) COVID-19
vaccines decline rapidly and require repeated boosting. Objective To evaluate the …